Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 51

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 51
---
 tag along rights upon a sale event. |

34

Equity Grant Timing Prior to our initial public offering in February 2025, we were a private company. Following our initial public offering, we grant equity awards in accordance with our equity award grant policy, which provides that we will generally grant new hire and promotion grants on a monthly basis effective on the first day of the month following the date on which a grantee’s employment begins or promotion occurs, as applicable; annual grants on an annual basis in the first calendar quarter; and special or off-cyclegrants on a periodic basis. During 2024, we were not a publicly traded company and, as such, did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, 10-Kor 8-Kthat disclosed material nonpublic information. Compensation Risk Assessment We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our pay-for-performancecompensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us. Employee Compensation Plan Information The following table provides information as of December 31, 2024 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.

| Plan Category                                              |     | Equity Compensation Plan Information 
 Number of                            
 securities to be                     
 issued upon                          
 exercise of                          
 outstanding                          
 options,                             
 warrants and                         
 rights                               |           |     | Weighted       
 average        
 exercise price 
 of outstanding 
 options,       
 warrants and   
 rights(1)      |      |     | Number of        
 securities       
 remaining        
 available for    
 future issuance  
 under equity     
 compensation     
 plans (excluding 
 securities       
 in first column) |           |    |
|:-----------------------------------------------------------|:----|:-------------------------------------|----------:|:----|:---------------|-----:|:----|:-----------------|----------:|---:|
| Equity compensation plans approved by security holders(2)  |     |                                      | 3,700,335 |     | $              | 5.87 |     |                  | 1,035,918 | -3 |
| Equity compensation plans